title: [Trimethoprim in the therapy of symptomatic liver porphyria].
abstract: Administration of antimalaria drugs to patients with symptomatic hepatic porphyria (porphyria cutanea tarda) at the First Medical Clinic made it possible due to previous experimental studies, to influence the porphyrim metabolism of yeasts. The effect of trimetoprim was investigated in clinical work in 12 hitherto not treated patients with the manifest form of symptomatic hepatic porphyria. The group comprised 9 men, mean age 56.4 years, and 3 women mean age 43.6 years. During the two-year clinical study dermatological symptoms of the disease became milder or receded. Concurrently there was a significant regression of porphyrinuria. In the whole group porphyrinuria declined to 11% of the original values. The porphyrin content of hepatic tissue declined considerably after two years treatment. In the group as a whole to 40% of the original values. Trimetoprim is another drug which influences porphyrin metabolism. The authors did not detect any undesirable side-effects of trimetoprim treatment. The effect of trimetoprim on clinical and biochemical parameters of the disease is less marked than the effect of chloroquine. This new treatment can be used in patients resistant to chloroquine or in combination with other anti-malaria drugs.
authors.affiliation: I. interní klinika 1. LF UK, Praha.
authors.forename: M
authors.initials: M
authors.lastname: Kaláb
authors.forename: P
authors.initials: P
authors.lastname: Kotal
authors.forename: M
authors.initials: M
authors.lastname: Jirsa
authors.forename: J
authors.initials: J
authors.lastname: Petrtýl
authors.forename: J
authors.initials: J
authors.lastname: Vrana
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017094:Porphyrias, Hepatic / Q000188:drug therapy*; D014295:Trimethoprim / Q000627:therapeutic use*
chemical_list: D014295:Trimethoprim